



AnnJi Now Recruiting for KD Clinical Trial

AnnJi Pharmaceutical's clinical trial of AJ201 for the treatment of Kennedy's Disease is now open for enrollment at the first U.S. site.

Approximately 24 participants will be assigned to receive an investigational study drug or placebo in this clinical trial. The trial is for males 18 years of age or older with Kennedy's Disease and symptomatic muscle weakness.

This clinical trial is evaluating an investigational study drug called AJ201 to learn how safe and tolerable it is in adult male participants with Kennedy's Disease. AJ201 will be compared to placebo, a substance that looks like the investigational study drug but has no active drug in it. An investigational study drug is one that is not approved for use by the general public.

The University of California, Irvine (UCI) is the first U.S. site enrolling patients. Information on other sites will be provided as it becomes available. A complete list of sites can be found on the "AnnJi Clinical Trial" link below.

The UCI Clinical trial coordinator is Pola Gaid,
Phone number: 714-456-6191

[AnnJi Clinical Trial](#)

[Frequently Asked Questions](#)

Kennedy's Disease Association | P.O. Box 1105, Coarsegold, CA 93614

[Unsubscribe info@kennedysdisease.org](mailto:info@kennedysdisease.org)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by info@kennedysdisease.org in collaboration
with



Try email marketing for free today!